米托蒽醌甲磺酸鹽作用機(jī)制 - Medchemexpress - MCE中國(guó)

1、Product Data SheetMitoquinone mesylateCat. No.: HY-100116ACAS No.: 845959-50-4分式: CHOPS分量: 678.81作靶點(diǎn): Reactive Oxygen Species作通路: Immunology/Inflammation; Metabolic Enzyme/Protease; NF-B儲(chǔ)存式: Pure form -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (73.66 mM; Need

2、 ultrasonic)H2O : 0.1 mg/mL (insoluble)SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 1.4732 mL 7.3658 mL 14.7317 mL5 mM 0.2946 mL 1.4732 mL 2.9463 mL10 mM 0.1473 mL 0.7366 mL 1.4732 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，

3、-20C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都?qǐng)先按照 In Vitro 式配制澄清的儲(chǔ)備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄 的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的式助溶1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.68 mM); Clear solution此案可

4、獲得 2.5 mg/mL (3.68 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.68 mM); Suspended solution; Need ultrasonicPage 1 of 2 www.MedChemE此案可獲得 2.5 m

5、g/mL (3.68 mM) 的均勻懸濁液，懸濁液可于服和腹腔注射。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (3.68 mM); Precipitated solution; Need ultrasonic此案可獲得 2.5 mg/mL (3.68 mM)以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 油中，混合均勻。B

6、IOLOGICAL ACTIVITY物活性 Mitoquinone mesylate種 于TPP的線粒體靶向抗氧化劑，可防氧化損傷。體外研究 Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant.The optimal doses for Mitoquinone (MitoQ) andDecylTPP treatment are selected from dose-response experiments during 4-h cold storage (CS). The potentialprotective benefits

7、 of Mitoquinone treatment against CS injury are tested initially using MitoSOX Red, amitochondrial-targeted fluorescent dye that measures mitochondrial superoxide generation. Normal rat kidney (NRK)cells exposed to CS result in a 2-fold increase in fluorescence due to mitochondrial superoxide compar

8、ed withuntreated cells. Mitoquinone offers significant protection against CS-induced mitochondrial superoxide generation;whereas the control compound DecylTPP does not offer any protection. Mitoquinone treatment markedly decreasesmitochondrial superoxide generation, whereas kidneys treated with Decy

9、lTPP have comparable levels ofmitochondrial superoxide to kidneys exposed to CS alone1.體內(nèi)研究 Mitoquinone (MitoQ) treatment significantly reduces pancreatic oedema and neutrophil infiltration. MitoQ dose-dependently increases serum amylase with an approximate doubling at the higher dose. MitoQ treatme

10、nt nearlydoubles lung MPO activity induced by Caerulein with a significant increase of serum IL-6 levels also evident at 10mg/kg (dose 1)2.PROTOCOLCell Assay 1 Normal rat kidney proximal tubular cells (NRK-52E) are maintained in six-well 100 or 150-mm, or 150-mm plates in ahumidified incubator gasse

11、d with 5% CO2 and 95% air at 37C in DMEM containing 5% fetal calf serum (FCS). Cellsare grown to 60% confluence and divided into four treatment groups: 1) untreated (Untx), 2) CS, 3) CS+Mitoquinone(MitoQ), and 4) CS+DecylTPP. Untreated cells remained at 37C in DMEM containing 5% FCS (group 1). CS is

12、 initiatedby washing cells with cold PBS twice and storing them in UW/Viaspan solution alone (4 h at 4C) (group 2),CS+Mitoquinone (1 M) (group 3), or CS+DecylTPP (1 M) (group 4). In separate experiments, cells are exposed toCS plus RW by replacing UW solution alone or UW solution containing Mitoquin

13、one or DecylTPP with DMEMcontaining 5% FCS overnight (18 h at 37C)1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice2Administration 2 Male CD1 mice (30-35 g) or C57BL/6J mice (20-25 g) are used. Seven intraperitoneal injections of a supramaxi

14、maldose (50 g/kg) of Caerulein, a CCK-8 analogue, are given on an hourly basis to induce hyperstimulation acutepancreatitis (CER-AP). Control mice receive equal volumes of PBS injection. In the Mitoquinone treatment groups,Mitoquinone at 10 mg/kg (dose 1) or 25 mg/kg (dose 2) is given at the first a

15、nd third injections of Caerulein.Similarly, dTPP at 9.6 mg/kg (dose 1) or 24 mg/kg (dose 2) is given for the dTPP treatment group. Mitoquinone anddTPP are at the same molar concentration at doses 1 and 2. Mice are sacrificed at 12 h after the first Caeruleininjection to collect samples. Bile acid-in

16、duced AP is achieved by retrograde infusion of TLCS into the pancreatic ductPage 2 of 3 www.MedChemE(TLCS-AP). After induction of anesthesia, TLCS applied using a mini infusion pump at a speed of 5 L/min for 10minutes. Successful infusion of TLCS into pancreas is demonstrated by a diffuse light blue

17、 colour (methylene blue)appearing in the pancreatic head. Control mice receive sham surgery without TLCS infusion. In the treatment groups,Mitoquinone (10 mg/kg) or dTPP (9.6 mg/kg) is given at 1 h and 3 h after TLCS infusion. Mice are sacrificed at 24 hafter the TLCS infusion or sham surgery.MCE ha

18、s not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19635-19645. Chem Eng J. 2020 May. Oxid Med Cell Longev. 2020 Mar. Oxid Med Cell Longev. 2019 Dec. J Neurosci Res. 2019 Aug 16.See more customer validations on HYPERLINK www.